ArticleAmerican journal of ophthalmology case reports2020
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis.
Article in American journal of ophthalmology case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.The Australasian journal of dermatology · 2022Pooled it
- Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan.Japanese journal of ophthalmology · 2026Review
- Ocular Side Effects of Dupilumab: A Comprehensive Overview of the Literature.Journal of clinical medicine · 2025Review
- Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease.Journal of ophthalmic inflammation and infection · 2024Article
- Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.BMJ open ophthalmology · 2022Article
- Dupilumab-induced ocular surface disease: a primer.BMJ case reports · 2022Article
- Dupilumab-associated ulcerative keratitis.International journal of ophthalmology · 2022Article
- Practical Management of Patients with Atopic Dermatitis on Dupilumab.Dermatology and therapy · 2021Article
- A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2021Review
- Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey.Dermatitis : contact, atopic, occupational, drugArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. OBSERVATIONS: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy. Symptoms resolved with topical prednisolone and discontinuation of the systemic therapy with dupilumab. CONCLUSION AND IMPORTANCE: Dupilumab is known to cause ocular surface inflammation, but we report a novel association between dupilumab use and potentially sight-threatening corneal ulceration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.